Adi Hoess, Affimed CEO (Affimed)

AACR: Ger­many's small NK cell play­er Af­fimed makes a big splash with ear­ly lym­phoma da­ta

Ger­man small-cap Af­fimed has long been high­light­ed as a po­ten­tial Cin­derel­la sto­ry, win­ning mile­stone-rich deals with Genen­tech and Roivant. And on Fri­day the biotech con­tin­ued its NK cell march, pre­sent­ing the first look at in-hu­man da­ta ahead of this week­end’s AACR con­fer­ence.

Re­searchers saw sig­nif­i­cant dis­ease re­duc­tion in all four lym­phoma pa­tients dosed with Af­fimed’s ex­per­i­men­tal off-the-shelf NK cell ther­a­py, with two reg­is­ter­ing com­plete re­spons­es as of the March 31 da­ta cut­off, the com­pa­ny an­nounced. All of the pa­tients had been heav­i­ly pre­treat­ed — with a range of four to 14 lines of pri­or ther­a­py — and there were no signs of cy­tokine re­lease syn­drome, tox­i­c­i­ty or graft-ver­sus-host dis­ease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.